Nuclear protein 1 promotes pancreatic cancer development and protects cells from stress by inhibiting apoptosis

Journal of Clinical Investigation

Volumn 122, Issue 6, 2012, Pages 2092-2103

  Hamidi, Tewfik ^a   Algül, Hana ^b   Cano, Carla Eliana ^a   Sandi, Maria José ^a   Molejon, Maria Inés ^a   Riemann, Marc ^c   Calvo, Ezequiel Luis ^d   Lomberk, Gwen ^e   Dagorn, Jean Charles ^a   Weih, Falk ^c   Urrutia, Raul ^e   Schmid, Roland Michael ^b   Iovanna, Juan Lucio ^a,f  

^a AIX MARSEILLE UNIVERSITY   (France)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c FRITZ LIPMANN INSTITUTE   (Germany)

^d LAVAL UNIVERSITY   (Canada)

^e MAYO CLINIC   (United States)

^f Campus de Luminy ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEAR PROTEIN; NUCLEAR PROTEIN 1; TRANSCRIPTION FACTOR RELB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CARCINOGENESIS; CELL PROTECTION; CELL STRESS; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMEDIATE EARLY GENE; IMMEDIATE EARLY RESPONSE 3 GENE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE K RAS; PANCREAS ADENOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA; ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DNA-BINDING PROTEINS; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMEDIATE-EARLY PROTEINS; MALE; MEMBRANE PROTEINS; MICE; MICE, MUTANT STRAINS; NEOPLASM PROTEINS; NEOPLASMS, EXPERIMENTAL; ONCOGENE PROTEIN P21(RAS); PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR RELB;

EID: 84861821128     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI60144     Document Type: Article

References (58)

1. Sultana A, et al. Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer. 2007;96(8):1183-1190. (Pubitemid 46625082)
2. O'Reilly EM, Lutz MP, Neuhaus P. Accomplishments in 2008 in the management of localized pancreatic cancer. Gastrointest Cancer Res. 2009;3(5 Supplement 2):S37-S42.
3. Burris H, Storniolo AM. Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil. Eur J Cancer. 1997;33(suppl 1):S18-S22.
4. Wong HH, Lemoine NR. Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nat Rev Gastroenterol Hepatol. 2009;6(7):412-422.
5. Olive KP, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009;324(5933):1457-1461.
6. Esposito I, et al. Tumor-suppressor function of SPARC-like protein 1/Hevin in pancreatic cancer. Neoplasia. 2007;9(1):8-17. (Pubitemid 46203930)
7. Goruppi S, Iovanna JL. Stress-inducible protein p8 is involved in several physiological and pathological processes. J Biol Chem. 2010;285(3):1577-1581.
8. Ito Y, et al. Expression of p8 protein in breast carcinoma; an inverse relationship with apoptosis. Anticancer Res. 2005;25(2A):833-837. (Pubitemid 40546851)
9. Ito Y, et al. Expression of p8 protein in medullary thyroid carcinoma. Anticancer Res. 2005;25(5):3419-3423. (Pubitemid 41105219)
10. Su SB, et al. Overexpression of p8 is inversely correlated with apoptosis in pancreatic cancer. Clin Cancer Res. 2001;7(5):1320-1324.
11. Su SB, et al. Expression of p8 in human pancreatic cancer. Clin Cancer Res. 2001;7(2):309-313.
12. Ree AH, Pacheco MM, Tvermyr M, Fodstad O, Brentani MM. Expression of a novel factor, com1, in early tumor progression of breast cancer. Clin Cancer Res. 2000;6(5):1778-1783. (Pubitemid 30305071)
13. Bratland A, et al. Expression of a novel factor, com1, is regulated by 1,25-dihydroxyvitamin D3 in breast cancer cells. Cancer Res. 2000;60(19):5578-5583.
14. Garcia-Montero A, Vasseur S, Mallo GV, Soubeyran P, Dagorn JC, Iovanna JL. Expression of the stress-induced p8 mRNA is transiently activated after culture medium change. Eur J Cell Biol. 2001;80(11):720-725. (Pubitemid 34092940)
15. Garcia-Montero AC, et al. Transforming growth factor beta-1 enhances Smad transcriptional activity through activation of p8 gene expression. Biochem J. 2001;357(pt 1):249-253. (Pubitemid 32642923)
16. Jiang YF, Vaccaro MI, Fiedler F, Calvo EL, Iovanna JL. Lipopolysaccharides induce p8 mRNA expression in vivo and in vitro. Biochem Biophys Res Commun. 1999;260(3):686-690. (Pubitemid 29371112)
17. Kallwellis K, Grempler R, Gunther S, Path G, Walther R. Tumor necrosis factor alpha induces the expression of the nuclear protein p8 via a novel NF kappaB binding site within the promoter. Horm Metab Res. 2006;38(9):570-574. (Pubitemid 44569140)
18. Mallo GV, et al. Cloning and expression of the rat p8 cDNA, a new gene activated in pancreas during the acute phase of pancreatitis, pancreatic development, and regeneration, and which promotes cellular growth. J Biol Chem. 1997;272(51):32360-32369. (Pubitemid 28011918)
19. Motoo Y, Iovanna JL, Mallo GV, Su SB, Xie MJ, Sawabu N. P8 expression is induced in acinar cells during chronic pancreatitis. Dig Dis Sci. 2001;46(8):1640-1646. (Pubitemid 32727093)
20. Passe CM, Cooper G, Quirk CC. The murine p8 gene promoter is activated by activating transcription factor 4 (ATF4) in the gonadotrope-derived LbetaT2 cell line. Endocrine. 2006;30(1):81-91. (Pubitemid 46020334)
21. Su SB, Motoo Y, Iovanna JL, Xie MJ, Sawabu N. Effect of camostat mesilate on the expression of pancreatitis-associated protein (PAP), p8, and cytokines in rat spontaneous chronic pancreatitis. Pancreas. 2001;23(2):134-140. (Pubitemid 32692122)
22. Sun Y, Liu Z, Zhang S. Tissue distribution, developmental expression and up-regulation of p8 transcripts on stress in zebrafish. Fish Shellfish Immunol. 2009;28(4):549-554.
23. Giroux V, et al. p8 is a new target of gemcitabine in pancreatic cancer cells. Clin Cancer Res. 2006;12(1):235-241. (Pubitemid 43166199)
24. Cano CE, Iovanna JL. Stress proteins and pancreatic cancer metastasis. ScientificWorldJournal. 2010;10:1958-1966.
25. Gironella M, et al. p8/nupr1 regulates DNA-repair activity after double-strand gamma irradiation- induced DNA damage. J Cell Physiol. 2009;221(3):594-602.
26. Aguirre AJ, et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev. 2003;17(24):3112-3126. (Pubitemid 38040774)
27. Hingorani SR, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005;7(5):469-483. (Pubitemid 40719130)
28. Siveke JT, Einwachter H, Sipos B, Lubeseder-Martellato C, Kloppel G, Schmid RM. Concomitant pancreatic activation of Kras(G12D) and Tgfa results in cystic papillary neoplasms reminiscent of human IPMN. Cancer Cell. 2007;12(3):266-279. (Pubitemid 47333415)
29. Vasseur S, et al. p8 improves pancreatic response to acute pancreatitis by enhancing the expression of the anti-inflammatory protein pancreatitis-associated protein I. J Biol Chem. 2004;279(8):7199-7207. (Pubitemid 38248867)
30. Hruban RH, et al. Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res. 2006;66(1):95-106. (Pubitemid 43166014)
31. Ito Y, et al. Expression and cellular localization of p8 protein in thyroid neoplasms. Cancer Lett. 2003;201(2):237-244. (Pubitemid 37357173)
32. Wang Z, et al. Activated K-ras and INK4a/Arf deficiency cooperate during the development of pancreatic cancer by activation of Notch and NF-kappaB signaling pathways. PLoS One. 2011;6(6):e20537.
33. Morton JP, et al. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci U S A. 2010;107(1):246-251.
34. Zhang Y, Schlossman SF, Edwards RA, Ou CN, Gu J, Wu MX. Impaired apoptosis, extended duration of immune responses, and a lupus-like autoimmune disease in IEX-1-transgenic mice. Proc Natl Acad Sci U S A. 2002;99(2):878-883. (Pubitemid 34106604)
35. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 1996;87(2):159-170. (Pubitemid 26358996)
36. Lomberk G, Mathison AJ, Grzenda A, Urrutia R. The sunset of somatic genetics and the dawn of epigenetics: a new frontier in pancreatic cancer research. Curr Opin Gastroenterol. 2008;24(5):597-602.
37. Dejardin E. The alternative NF-kappaB pathway from biochemistry to biology: pitfalls and promises for future drug development. Biochem Pharmacol. 2006;72(9):1161-1179. (Pubitemid 44479741)
38. Guerin S, Baron ML, Valero R, Herrant M, Auberger P, Naquet P. RelB reduces thymocyte apoptosis and regulates terminal thymocyte maturation. Eur J Immunol. 2002;32(1):1-9. (Pubitemid 34092816)
39. Feng B, et al. Small interfering RNA targeting RelB protects against renal ischemia-reperfusion injury. Transplantation. 2009;87(9):1283-1289.
40. Josson S, Xu Y, Fang F, Dhar SK, St Clair DK, St Clair WH. RelB regulates manganese superoxide dismutase gene and resistance to ionizing radiation of prostate cancer cells. Oncogene. 2006;25(10):1554-1559. (Pubitemid 43361940)
41. Nishina T, Yamaguchi N, Gohda J, Semba K, Inoue J. NIK is involved in constitutive activation of the alternative NF-kappaB pathway and proliferation of pancreatic cancer cells. Biochem Biophys Res Commun. 2009;388(1):96-101.
42. Wharry CE, Haines KM, Carroll RG, May MJ. Constitutive non-canonical NFkappaB signaling in pancreatic cancer cells. Cancer Biol Ther. 2009;8(16):1567-1576.
43. Sasada T, et al. Prognostic significance of the immediate early response gene X-1 (IEX-1) expression in pancreatic cancer. Ann Surg Oncol. 2008;15(2):609-617.
44. Bruheim S, Xi Y, Ju J, Fodstad O. Gene expression profiles classify human osteosarcoma xenografts according to sensitivity to doxorubicin, cisplatin, and ifosfamide. Clin Cancer Res. 2009;15(23):7161-7169.
45. Gonzalez S, Perez-Perez MM, Hernando E, Serrano M, Cordon-Cardo C. p73beta-Mediated apoptosis requires p57kip2 induction and IEX-1 inhibition. Cancer Res. 2005;65(6):2186-2192. (Pubitemid 40490126)
46. Ria R, et al. Gene expression profiling of bone marrow endothelial cells in patients with multiple myeloma. Clin Cancer Res. 2009;15(17):5369-5378.
47. Garcia J, Ye Y, Arranz V, Letourneux C, Pezeron G, Porteu F. IEX-1: a new ERK substrate involved in both ERK survival activity and ERK activation. EMBO J. 2002;21(19):5151-5163.
48. Wu MX, Ao Z, Prasad KV, Wu R, Schlossman SF. IEX-1L, an apoptosis inhibitor involved in NF-kappaB-mediated cell survival. Science. 1998;281(5379):998-1001. (Pubitemid 28399251)
49. Arlt A, et al. IEX-1 directly interferes with RelA/p65 dependent transactivation and regulation of apoptosis. Biochim Biophys Acta. 2008;1783(5):941-952.
50. Vasseur S, et al. Structural and functional characterization of the mouse p8 gene: promotion of transcription by the CAAT-enhancer binding protein alpha (C/EBPalpha) and C/EBPbeta transacting factors involves a C/EBP cis-acting element and other regions of the promoter. Biochem J. 1999;343(pt 2):377-383. (Pubitemid 29511771)
51. Carracedo A, et al. Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Res. 2006;66(13):6748-6755. (Pubitemid 44085633)
52. Archange C, et al. The WSB1 gene is involved in pancreatic cancer progression. PLoS One. 2008;3(6):e2475.
53. Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 1979;18(24):5294-5299. (Pubitemid 10140274)
54. Malicet C, Lesavre N, Vasseur S, Iovanna JL. p8 inhibits the growth of human pancreatic cancer cells and its expression is induced through pathways involved in growth inhibition and repressed by factors promoting cell growth. Mol Cancer. 2003;2:37.
55. Gu G, Dubauskaite J, Melton DA. Direct evidence for the pancreatic lineage: NGN3+ cells are islet progenitors and are distinct from duct progenitors. Development. 2002;129(10):2447-2457. (Pubitemid 34863851)
56. Powolny-Budnicka I, Riemann M, Tänzer S, Schmid RM, Hehlgans T, Weih F. RelA and RelB transcription factors in distinct thymocyte populations control lymphotoxin-dependent interleukin-17 production in γδ T cells. Immunity. 2011;34(3):364-374.
57. Charpin C, et al. Validation of an immunohistochemical signature predictive of 8-year outcome for patients with breast carcinoma [published online ahead of print January 3, 2012]. Int J Cancer. doi:10.1002/ijc.27371.
58. Giusiano S, et al. Immunohistochemical profiling of node negative breast carcinomas allows prediction of metastatic risk. Int J Oncol. 2010;36(4):889-898.